- Home
- ONFO vs SNPX Comparison
ONFO vs SNPX Comparison
Compare ONFO & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- SNPX
- Stock Information
- Founded
- ONFO 2018
- SNPX 2012
- Country
- ONFO United States
- SNPX United States
- Employees
- ONFO N/A
- SNPX N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- ONFO Technology
- SNPX Health Care
- Exchange
- ONFO Nasdaq
- SNPX Nasdaq
- Market Cap
- ONFO 4.5M
- SNPX 4.1M
- IPO Year
- ONFO 2022
- SNPX N/A
- Fundamental
- Price
- ONFO $1.30
- SNPX $2.40
- Analyst Decision
- ONFO
- SNPX Strong Buy
- Analyst Count
- ONFO 0
- SNPX 1
- Target Price
- ONFO N/A
- SNPX $14.00
- AVG Volume (30 Days)
- ONFO 24.9K
- SNPX 18.6K
- Earning Date
- ONFO 11-15-2024
- SNPX 11-12-2024
- Dividend Yield
- ONFO N/A
- SNPX N/A
- EPS Growth
- ONFO N/A
- SNPX N/A
- EPS
- ONFO N/A
- SNPX N/A
- Revenue
- ONFO $6,590,171.00
- SNPX N/A
- Revenue This Year
- ONFO $133.59
- SNPX N/A
- Revenue Next Year
- ONFO N/A
- SNPX N/A
- P/E Ratio
- ONFO N/A
- SNPX N/A
- Revenue Growth
- ONFO 29.25
- SNPX N/A
- 52 Week Low
- ONFO $0.39
- SNPX $2.32
- 52 Week High
- ONFO $1.80
- SNPX $8.78
- Technical
- Relative Strength Index (RSI)
- ONFO 58.89
- SNPX 33.10
- Support Level
- ONFO $1.04
- SNPX $2.88
- Resistance Level
- ONFO $1.15
- SNPX $3.20
- Average True Range (ATR)
- ONFO 0.13
- SNPX 0.19
- MACD
- ONFO -0.01
- SNPX -0.06
- Stochastic Oscillator
- ONFO 62.00
- SNPX 8.88
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.